Revenue distribution by industry:

• Pharmaceuticals: 60%
• Medical devices: 25%
• Biotechnology: 15%

TOP 3 markets and their percentage shares:

• South Korea: 40%
• USA: 30%
• China: 20%

PharmaResearch Co., Ltd. generates the majority of its revenue from the pharmaceutical industry, followed by medical devices and biotechnology. The domestic market in South Korea is the largest single market, followed by the USA and China. These markets are crucial for the company as they offer both high demand and growth potential. The strong presence in these regions enables PharmaResearch to benefit from the respective healthcare systems and innovation capabilities of these markets.

Production Sites: South Korea

PharmaResearch Co., Ltd. mainly produces its products in South Korea. The company has strategically located its production facilities in the region to benefit from the well-developed infrastructure and skilled workforce. South Korea is known for its advanced technology and high standards in pharmaceutical production, enabling PharmaResearch Co., Ltd. to manufacture high-quality products.

Additionally, the company could expand its production capacity in other countries through partnerships or joint ventures to better serve the international market.

Focus on R&D Investments: 25% of revenue (2026)

Expansion of Product Pipeline: 5 new products in clinical Phase III (2026)

International Market Expansion: Target markets: USA and Europe (2026)

PharmaResearch Co., Ltd. is pursuing a growth strategy that heavily focuses on research and development (R&D). The company invests 25% of its revenue in R&D to expand its product pipeline and develop innovative therapies.

Currently, five new products are in clinical Phase III, indicating an imminent market launch. These products target various therapeutic areas to diversify the existing portfolio and tap into new market segments.

In addition, PharmaResearch plans an aggressive expansion into international markets, particularly in the USA and Europe. These markets offer significant growth opportunities due to their size and demand for innovative pharmaceutical solutions.

Main raw materials: Biotechnological materials, chemicals for pharmaceutical research

Import countries: USA, Germany, China

PharmaResearch Co., Ltd., a company specializing in biotechnological and pharmaceutical research, mainly imports biotechnological materials and special chemicals necessary for the development and production of their products. The USA and Germany are leading suppliers of high-quality biotechnological materials and research components, while China often serves as a source for more cost-effective chemical raw materials.

This import strategy enables PharmaResearch to source both high-quality and cost-effective materials to achieve their research and development goals. Diversifying suppliers across multiple countries also helps minimize risks in the supply chain.

Market share: 8% (2025, estimated) R&D investments: 12% of revenue (2025) Patent portfolio: 150 active patents (2025)

PharmaResearch Co., Ltd. has gained a significant competitive advantage through its strong investments in research and development. With 12% of revenue allocated to R&D, the company exceeds the industry average, highlighting its innovation capabilities.

The company owns an extensive patent portfolio with 150 active patents, further strengthening its position in the market. These patents not only secure existing products but also enable the development of new, innovative therapies.

The estimated market share of 8% indicates that PharmaResearch Co., Ltd. is well positioned in a competitive market environment. Through continuous innovation and strategic partnerships, the company can further expand its market position.

Institutional Investor Share: 42% (2026, estimated)
Insider Purchases: No significant purchases in the last 12 months
Insider Sales: 3% of shares in the last year

The institutional investor share at PharmaResearch Co., Ltd. is estimated at 42%. This indicates a moderate level of confidence from institutional investors in the company, which could suggest a stable financial performance and positive future prospects.

There have been no significant insider purchases in the last 12 months, which could indicate that management does not see any significant undervalued opportunities. However, about 3% of shares were sold by insiders, possibly due to profit-taking or personal financial decisions. Such sales should be considered in the context of overall performance and market conditions.

Market share of PharmaResearch Co., Ltd.: 5.2% (2026, estimated)

Top competitors and their market shares:

1. Samsung Biologics - 18.5%
2. Celltrion - 15.0%
3. SK Biopharmaceuticals - 10.3%
4. Hanmi Pharmaceutical - 8.7%
5. LG Chem Life Sciences - 7.5%
6. PharmaResearch Co., Ltd. - 5.2%
7. Daewoong Pharmaceutical - 4.8%
8. Yuhan Corporation - 4.5%
9. Green Cross Corporation - 3.9%
10. JW Pharmaceutical - 3.2%

Moat of PharmaResearch Co., Ltd.: Moderate

PharmaResearch Co., Ltd. has a moderate moat, mainly supported by specialized research and development as well as some patented products. Compared to larger competitors like Samsung Biologics and Celltrion, which have more extensive resources and broader product portfolios, PharmaResearch's moat is less pronounced.

Samsung Biologics and Celltrion have significant advantages due to their size, global presence, and comprehensive production capacities, giving them a stronger moat. These companies benefit from economies of scale and a diversified product line that help them secure and expand market shares.

PharmaResearch needs to focus on innovation and niche markets to strengthen its moat and compete against larger competitors.

Revenue Growth: 10.5% (2025) Research and Development Expenses: 18% of revenue (2025) Market Share in Asia: 12% (2025)

PharmaResearch Co., Ltd. recorded a revenue growth of 10.5% in 2025, attributed to successful market expansion and the introduction of new products. The company continues to heavily invest in research and development, with expenses accounting for 18% of revenue. This indicates a strong innovation pipeline that could support future growth.

The market share in Asia stands at 12%, signaling a solid market position in one of the fastest-growing regions in the world. These factors, combined with a robust R&D strategy, suggest that PharmaResearch Co., Ltd. is well positioned to capitalize on future market opportunities.

However, investors should also consider general market risks and the competitive landscape before making an investment decision.

Dividend Yield: 2.5% (estimated for 2026)
Dividend History: Steady payouts over the last 5 years

PharmaResearch Co., Ltd. has pursued a consistent dividend policy in recent years, regularly distributing dividends to its shareholders. The estimated dividend yield for 2026 is around 2.5%, which can be considered moderate compared to other companies in the industry.

The reliability of the payout can be rated as high, based on the company's past dividend history and stable financial performance. PharmaResearch Co., Ltd. has demonstrated in the past its ability to pay dividends even in economically challenging times. This indicates a solid financial strategy and a sustainable business model.